Arvinas Inc (ARVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arvinas Inc (ARVN) has a cash flow conversion efficiency ratio of -0.070x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.40 Million) by net assets ($433.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Arvinas Inc (ARVN) liquidity interval to measure how many days the company can operate on defensive assets alone.
Arvinas Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Arvinas Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arvinas Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arvinas Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kailong High Technology Co. Ltd.
SHE:300912
|
N/A |
|
Bowman Consulting Group Ltd
NASDAQ:BWMN
|
0.036x |
|
Wild Bunch AG
F:WBAH
|
-0.008x |
|
BlackRock Core Bond Closed Fund
NYSE:BHK
|
0.030x |
|
Shandong Xingmin Wheel Co Ltd
SHE:002355
|
0.003x |
|
KraussMaffei Co Ltd
SHG:600579
|
0.016x |
|
ACNB Corporation
NASDAQ:ACNB
|
0.030x |
|
Jinlong Machinery Electronic
SHE:300032
|
0.078x |
Annual Cash Flow Conversion Efficiency for Arvinas Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arvinas Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Arvinas Inc (ARVN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $433.90 Million | $-273.80 Million | -0.631x | -36.69% |
| 2024-12-31 | $561.70 Million | $-259.30 Million | -0.462x | +12.40% |
| 2023-12-31 | $660.00 Million | $-347.80 Million | -0.527x | -8.84% |
| 2022-12-31 | $564.90 Million | $-273.50 Million | -0.484x | -167.66% |
| 2021-12-31 | $781.70 Million | $559.40 Million | 0.716x | +612.02% |
| 2020-12-31 | $642.20 Million | $-89.76 Million | -0.140x | +22.01% |
| 2019-12-31 | $226.69 Million | $-40.63 Million | -0.179x | -51.97% |
| 2018-12-31 | $136.67 Million | $-16.12 Million | -0.118x | -100.57% |
| 2017-12-31 | $245.87K | $5.11 Million | 20.796x | +2675.61% |
| 2016-12-31 | $24.03 Million | $-19.40 Million | -0.807x | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more